Abstract:Preeclampsia is a type of hypertension that develops during pregnancy. It is one of the leading causes for maternal morbidity with consequences during and after pregnancy. Because of its diverse clinical presentation, preeclampsia is a uniquely challenging adverse pregnancy outcome to predict and manage. In this paper, we explore preeclampsia in a nulliparous study cohort with machine learning techniques to build a model that distinguishes between participants most at risk for morbidity, those with preeclampsia with severe features or eclampsia, and the class of no pregnancy-related hypertension. We curated the dataset for this secondary analysis using only training examples that have all known biomarkers, factors, and placental analytes. We built classification models at discrete time points in pregnancy that combine risk factors for preeclampsia with severe features or eclampsia to help screen cases early in pregnancy. The time points are at 6 − 136 (V1), 16 − 216 (V2), 22 − 296 (V3) weeks gestation and at delivery (V4). We then analyzed the model prediction results and provided an interpretable report of cut-off points of the top contributing risk factors and their impact on prediction. Finally, we identified race-based biases in our models and describe how we mitigate those biases. We evaluated the results of four machine learning algorithms and found that ensemble methods outperformed non-ensemble methods. Random Forest models achieved an area under receiver operating characteristic curve at V1 of 0.68 ± 0.05, V2 of 0.73 ± 0.05, V3 of 0.76 ± 0.04 and V4 of 0.83 ± 0.03. Analyzing the Random Forest models, the features found to be most informative across all visits fall into several broad categories: weight, blood pressure measurements, uterine artery doppler measurements, diet intake and serum biomarkers. We found that our models are biased toward non-Hispanic black participants with a high predictive equality ratio of 1.31. We corrected this bias and reduced this ratio to 1.14. We also evaluated results for predictions of early cases versus late preeclampsia with severe features or eclampsia and found that placental analytes as the top contributors in model feature importance. Random Forest for this analysis achieved an area under receiver operating characteristic curve at V1 of 0.63 ± 0.11, V2 of 0.79 ± 0.11, V3 of 0.83 ± 0.08 and V4 of 0.84 ± 0.09. Our experiments suggest that it is important and possible to create screening models to predict the participants at risk of developing preeclampsia with severe features and eclampsia. The top features stress the importance of using several tests, in particular tests for biomarkers and ultrasound measurements. The models could be used as a screening tool as early as 6-13 weeks gestation to help clinicians identify participants who may subsequently develop preeclampsia, confirming the cases they suspect or identifying unsuspected cases. The proposed approach is easily adaptable to address any adverse pregnancy outcome with fairness.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThis work was supported by NIH/NLM ([www.nlm.nih.gov][1]) grant R01LM013327### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subjects approval for this study, titled "SCH: Prediction of Preterm Birth in Nulliparous Women", was obtained following review by Columbia University Human Subjects Institutional Review Board under number IRB-AAAR9413, and the City University of New York CUNY HRPP/IRB review number 2019-0855. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript [1]: http://www.nlm.nih.gov

Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy

Using machine learning to predict the risk of developing hypertensive disorders of pregnancy using a contemporary nulliparous cohort

Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth

Late first trimester circulating microparticle proteins predict the risk of preeclampsia < 35 weeks and suggest phenotypic differences among affected cases

Predicting Hypertensive Disease in the First Trimester of Pregnancy: Risk Models and Analysis of Serum D-dimer Levels Combined with Plasma Pregnancy-Associated Protein A, Free β-Subunit of Human Chorionic Gonadotropin, and Fetal Nuchal Translucency

Early Prediction of Hypertensive Diseases of Pregnancy by Using Combined Screening Methods in a Rural Population

Feasibility of using a multivariate serum biomarker model in early pregnancy to predict gestational hypertension

Risk factors and prediction model for new-onset hypertensive disorders of pregnancy: a retrospective cohort study

Differences in Cardiometabolic Proteins in Pregnancy Prioritize Relevant Targets of Preeclampsia

Prediction of future chronic hypertension from maternal characteristics in early pregnancy

Proteomic Profiles of Maternal Plasma Extracellular Vesicles for Prediction of Preeclampsia

Elevated Cardiovascular Biomarkers Following Hypertensive Disorder of Pregnancy

Analysis of Predictive Information From Biomarkers Added to Clinical Models of Preeclampsia: Consideration of PAPP-A2, Activin A, and sFlt-1:PlGF Ratio

A Second Trimester Prediction Algorithm for Early-Onset Hypertensive Disorders of Pregnancy Occurrence and Severity Based on Soluble fms-like Tyrosine Kinase 1 (sFlt-1)/Placental Growth Factor (PlGF) Ratio and Uterine Doppler Ultrasound in Women at Risk

Second trimester maternal serum D-dimer combined with alpha-fetoprotein and free β-subunit of human chorionic gonadotropin predict hypertensive disorders of pregnancy: a systematic review and retrospective case–control study

Preeclampsia Predictor with Machine Learning: A Comprehensive and Bias-Free Machine Learning Pipeline

Prediction of adverse maternal and perinatal outcomes associated with pre-eclampsia and hypertensive disorders of pregnancy: a systematic review and meta-analysis

Epigenetic phenotype of plasma cell-free DNA in the prediction of early-onset preeclampsia

Pre-pregnancy Dietary Intake of Omega-3 and Omega-6 Fatty Acids and the Risk of Hypertensive Disorders of Pregnancy

Predicting Preterm Birth Using Proteomics

Polygenic prediction of preeclampsia and gestational hypertension